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ABSTRACT 
Objective: The purpose of the study was to synthesize prodrugs of mefenamic acid, to be used as Anti inflammatory drug with fewer adverse 
effects. 
Methods: The drug was covalently bonded to PEG 1500 (polyethylene glycol) and PEG 6000 as such and with a linker glycine. The prodrugs were 
characterized by FT-I.R and N.M.R. For the drug release studies, all the prodrugs were subjected to pH 1.2 and pH 7.2. For the anti inflammatory 
activity, Carrageenan induced rat paw edema method was followed and for Ulcer protecting activity, Pylorus ligation method was used, the 
prodrugs were administered to male Sprague-Dawley rats. 
Results: The results suggested that the prodrugs of mefenamic acid, the drug release was higher at pH 7.2 than at pH 1.2. The result obtained for 
anti inflammatory activity was comparable to the standard drug of mefenamic acid. For ulcers, the prodrugs were found to possess Ulcer curing 
property higher than the standard drug. 
Conclusion: The prodrugs thus synthesized possess anti inflammatory activity as well as good ulcer protecting activity, can be used instead of 
standard drug. 
Keywords: Polyethylene glycol, Mefenamic acid, Ulcer protecting, Anti inflammatory, Prodrugs.  
 
INTRODUCTION 
Mefenamic acid is an NSAID, derivative of N-aryl anthranilic acid 
belonging to class of fenamic acids. It is chemically N-(2,3-xylyl) 
anthranilic acid [1, 2, 3]. The drug is used for its analgesic, anti 
inflammatory activity [4], and primary dysmenorrhea. The dose of the 
drug used is 500 mg as initial dose followed by 250 mg every 6 hrs and 
not to continue more than a week. The mechanism of action [5, 6, 7] of 
mefenamic acid is inhibition of cyclooxygenase (COX) enzymes which 
are required for production of prostaglandins. The adverse effects of the 
drug include ulcer formation in the upper GI tract [2, 3]. 
Prodrugs 
Polymeric prodrug approach is one of the method where in a drug is 
covalently bonded to a polymer [8]. The requirements of prodrug 
are it should be chemically or enzymatically cleavable, non toxic and 
no pharmacological activity as such [9, 10]. Prodrugs are classified 
as Carrier linked prodrugs, Tripartite prodrugs, Mutual prodrugs, 
Polymeric prodrugs and Bioprecursor [10]. The use of polymers was 
first introduced by Prof. H. Ringsdorf [11]. Polymers have been used 
as carriers and backbone for many drugs which are biodegradable 
[12]. The commonly used polymers are polyethylene glycol, 
polyvinyl pyrrolidone (PVP). Polyethylene glycol is a non 
biodegradable polymer but, excreted easily [13]. Many drugs are 
conjugated to polyethylene glycol of varying molecular weights [14, 
15]. Polyethylene glycol-acyclovir prodrugs [16] were synthesized 
and prodrugs of aspirin were synthesized using HEMA (Hydroxy 
ethyl methacrylate) as polymers [17]. PEG 6000 was used as 
polymer for preparation of solid dispersions of aceclofenac and was 
evaluated for particle size and dissolution rate [18]. Polymer-drug 
conjugates are synthesized covalently by ester, anhydride, amide 
linkages [19, 20]. Use of polyethylene glycol as polymeric backbone 
to drugs for drug delivery is known as PEGylation [21]. Mefenamic 
acid sustained release tablets have been formulated using sodium 
alginate to form water insoluble gel [22]. Mefenamic acid solubility 
was increased using HPMC (Hydroxy propyl methyl cellulose) by 
spherical agglomeration technique [23]. Mefenamic acid mutual prodrug 
was synthesized using glucosamine [24]. Based on the facts, the thought 
for synthesizing prodrugs of mefenamic acid using polyethylene glycol 
1500 and 6000 as polymeric backbone has turned up. 
MATERIALS AND METHODS 
Mefenamic acid drug was obtained from Hetero Drugs, Hyderabad. 
PEG 1500, PEG 6000, DMF (di methyl formamide), DCC (dicyclohexyl 
carbodiimide), DMAP (dimethyl amino pyridine), Glycine and other 
solvents of reagent grade were purchased from SD Fine chemicals. 
Animal studies were done in department of Pharmacology, 
Geethanjali College of Pharmacy, Keesara, Ghatkesar and it was 
approved by Institutional Animal Ethics Committee, Regd no: 
1648/PO/a/12/CPCSEA-GCOP-IAEC-03/2013 for anti inflammatory 
and ulcer protecting activity.  
Synthesis of PEG 1500/6000-Mefenamic acid 
PEG 1500/6000 1.5 gms and 1.6 ml of pyridine were taken in a 
round bottomed flask, to it a solution of DCC 1gm and 0.6 gms of 
DMAP in 10 ml DMF was added. The flask was kept in an ice bath 
and temperature was maintained 0o
Synthesis of PEG 1500/6000 glycine 
 C, to this mefenamic acid was 
added for 10 mints. The flask was then placed on a magnetic stirrer, 
attached with a condenser and was allowed for coupling reaction for 
7 days at room temperature. The residue obtained was dissolved in 
DCM (dichloro methane) and reprecipitated by excess of cold diethyl 
ether [25]. The product obtained was subjected to TLC (thin layer 
chromatography) using mobile phase DCM: methanol 3:2. Finally 
structure was confirmed (Scheme I) by FT-I.R and N.M.R. 
PEG 1500/6000 1.5 gms and 1.6 ml of pyridine were taken in a two 
necked round bottomed flask and 20 ml DMF was added and placed 
on a magnetic stirrer. To this 0.18 gms of glycine was added in small 
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portions for 3 hrs maintaining room temperature. Then the contents 


























 C for 21 hrs. The residue obtained was dissolved in DCM and 
reprecipitated by excess of cold diethyl ether. The formation of the 
product was subjected to TLC, mobile phase DCM: methanol 3:2 and 

















































Synthesis of PEG 1500/6000-glycine-Mefenamic acid 
A solution of DCC 1 gm in 10 ml of DMF and 0.6 gms of DMAP in 10 
ml of DMF were taken in a beaker. The mixture was added drop by 
drop to another beaker containing a solution of 0.4 gms of PEG 
1500/6000-glycine in 20 ml of DMF. Mefenamic acid 1 gm was 
added in portions to the above mixture at 0o
The coupling reaction was carried out for 7 days at room 
temperature. The residue obtained was dissolved in DCM and 
reprecipitated by excess of cold diethyl ether. The product was 
subjected to TLC, mobile phase DCM: methanol 3:2 and structures 
(Scheme II) were confirmed by FT-I.R and N.M.R. 
 C for 10 mints. The 
contents were transferred to a round bottomed flask fitted with a 
condenser and placed on magnetic stirrer.  
In vitro Drug Release Studies 
The synthesized prodrugs were checked for the drug release at pH 
1.2 and 7.2, temperature was maintained at 37o C. The λmax was 
determined for mefenamic acid and found to be 285 nm, aliquots of 
5 ml were collected at intervals of 0, 5, 10, 15, 30, 45, 60 mints, sink 
conditions were maintained. A standard graph was plotted and % 
drug release was found. A graph of time v/s cumulative drug release 
was plotted at pH 1.2 and 7.2. 
Anti inflammatory activity 
Male Sprague-Dawley rats weighing 100-150 gms were divided into 
6 groups. The method for this activity followed was Carrageenan 
induced rat paw edema. Ist group control, IInd group standard drug, 
IIIrd, IVth, Vth, VIth groups received mefenamic acid prodrugs, 
injected into the subplantar region in the left and right hind paws 
and the swelled volume was measured by Dolphin, India 
Plethysmometer. The measurements were taken at intervals of 1, 3, 
6 hrs [26]. The % inhibition was calculated by 
 
Ulcer protecting activity  
For this activity, the method followed was Pylorus-ligation. The 
animals weighing 100-150 gms were fastened overnight, 
anaesthetized, incised 1 cm long in abdomen below the sternum. The 
stomach was exposed and a thread was passed round pyloric 
sphincter, a knot was tied. Abdomen was closed with sutures and 
animals were kept in separate cage, allowed to recover.  
Ist group received control, IInd group received standard drug 
mefenamic acid 10 mg/kg, IIIrd, IVth, Vth, VIth groups were injected 
mefenamic acid prodrugs and after performing pylorus ligation kept 
in separate cages, after 4 hrs the animals were sacrificed and 
abdomen was cut open, stomach was removed and washed under 
running tap water, then placed on glass slide and observed on 
microscope at 10 X magnification for ulcers [27]. 




Table 1: Physical properties of Mefenamic acid prodrugs 
S. 
No. 
Compound Solubility Colour Melting 
Pint 
I.R Spectra N.M.R Spectra 
1 Mefenamic acid Methanol White 220-229o OH of COOH-2569, 2 
C 
0 2.1δ-2.4 δ (t, 6H) 2.5δ-(d, 2H) 6.7-7.5 δ 
(m, 7H) 7.9 δ (s, 1H), 9.5 δ (s, 1H). 
 NH-
3348, C=O-1647. 




White 200-208o 2 
C 
0 1.1-1.5δ-(m, 12H), 1.6-4.5δ (m, 44H), 
5.6-7.7δ (m, 14H), 7.9δ (d, 2H). 






White 225-234o 2 
C 
0 1.1-1.5δ (m, 12H) 1.6-4.5δ (m, 44H) 
5.6-7.5δ (m, 14H) 7.9δ(d, 2H). 
 NH-3327, 3124, C-O-C-
1157, CH-str-2850, C=O-1629. 




White 224-233o 2 
C 
0 1.1-1.5δ-(m, 12H), 1.6-4.5δ (m, 44H), 
5.6-7.7δ (m, 14H), 7.9δ (d, 2H). 






White 221-230o 2 
C 
0 1.1-1.5δ (m, 12H) 1.6-4.5δ (m, 44H) 
5.6-7.5δ (m, 14H) 7.9δ(d, 2H). 
 NH-3321, 2937, C-O-C-




Fig. 1: I.R Spectra of Mefenamic acid 
 
 
Fig. 2: I.R Spectra of PEG 1500/6000-mefenamic acid 
 
Fig. 3: I.R Spectra of PEG 1500/6000-Glycine-Mefenamic acid 
 
 
Fig. 4: N.M.R Spectra of Mefenamic acid 
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Fig. 5: N.M.R Spectra of PEG 1500/6000-mefenamic acid 
 
 
Fig. 6: N.M.R Spectra of PEG 1500/6000-Glycine-mefenamic acid 
 
Fig. 7: In vitro drug release profile of PEG 1500 prodrugs at pH 
1.2 and 7.2. 
 
 
Fig. 8: In vitro drug release profile of PEG 6000 prodrugs at pH 
1.2 and 7.2. 
 
Table 2: Anti inflammatory Activity 
Groups Change in Paw volume (ml) mean±SEM 
& % Inhibition 
1 hr 3 hr 6 hr 
Control 0.52±0.02 0.61±0.02 0.65±0.03 






































Values are mean±SEM, n=6, one way ANOVA p<0.05 vs control 
 
 
Fig. 9: Anti inflammatory activity of mefenamic acid prodrugs 
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Table 3: Gross Ulcer Index of Mefenamic acid prodrugs 
S. No. Treatment Ulcer Index 
1 Control 10 
2 Mefenamic acid 18 
3 PEG1500-Mefenamic acid 16 
4 PEG1500-Gly-Mefenamic acid 16 
5 PEG6000-Mefenamic acid 19 
6 PEG6000-Gly-Mefenamic acid 17 
 
 
Fig. 10: Ulcer Index of mefenamic acid prodrugs 
 
DISUSSION 
Prodrug approach is currently one of the popular approaches in the 
development of new drugs [28-35]. In this study, prodrugs of 
mefenamic acid were developed and investigated. The prodrugs 
were successfully synthesized. Upon synthesis, these were 
characterized for various parameters. The result obtained from 
spectral data (Sl.no 1 of table 1) indicated the standard drug had a 
COOH group by I.R and N.M.R. The structures of PEG 1500/6000-
mefenamic acid (Sl.No 2 and 4) were confirmed by I.R and N.M.R, 
that COOH group of mefenamic acid had formed an ester, the 
structures were given in scheme I.The structures for PEG 
1500/6000-glycine-mefenamic acid (Sl.No 3 and 5) by I.R and N.M.R, 
the carboxylic acid group of mefenamic acid had formed an amide 
linkage with the amino terminal of glycine, the structures were given 
in scheme II. Fig.1 and Fig.4 I.R and N.M.R spectras of standard drug 
mefenamic acid, Fig.2 and Fig.5 I.R and N.M.R spectras of PEG 
1500/6000-mefenamic acid, Fig.3 and Fig.6 I.R and N.M.R spectras 
of PEG 1500/6000-glycine-mefenamic acid. 
The drug release studies for the synthesized prodrugs were given in 
Fig.7 and Fig.8, the study revealed that drug release for PEG 1500-
mefenamic acid, PEG 1500-glycine-mefenamic acid, PEG 6000-
mefenamic acid and PEG 6000-glycine-mefenamic acid was more at 
pH 7.2 than at pH 1.2. Also the comparision study indicated that 
there is a role of spacer (glycine) in the drug release.  
Table 2 and Fig.9 were the results obtained for anti inflammatory 
activity of the prodrugs synthesized. The results were taken for 1 hr, 
3 hrs and 6 hrs for change in paw volume, out of the 4 prodrugs, 1 of 
the compound had better anti inflammatory activity than standard 
drug. 
Table 3 and Fig.10 indicated ulcer protecting activity for the 
synthesized prodrugs. The ulcer index was measured and out of 4 
prodrugs synthesized 3 of them were found to be more protecting 
towards ulcers than standard drug. The prodrugs which had more 
ulcer protecting activity are PEG 1500-mefenamic acid, PEG 1500-
glycine-mefenamic acid and PEG 6000-glycine-mefenamic acid. 
CONCLUSION 
The prodrugs of Mefenamic acid synthesized have retained their anti 
inflammatory activity similar to standard drug Mefenamic acid. An 
important finding of the result regarding ulcer protection that 
prodrugs of mefenamic acid have shown good ulcer protection than 
standard drug. 
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